RxDoctor Payments Data

Sarah Eisworth, NP

Family · Zachary, LANPI 1225393283

Payments from drug & device makers

$2,772in general payments, 2019–2025

Across 170 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$611
  • Lilly USA, LLC$274
  • Amgen$269
  • GSK$237
  • Novo Nordisk$194
  • Pfizer$171
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,772 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$17,405
Medicare patients
68
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$67,679
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$37,834
JardianceEmpagliflozin31$32,111
OzempicSemaglutide26$24,429
LinzessLinaclotide11$6,988
BelsomraSuvorexant11$4,636
Albuterol Sulfate HfaAlbuterol Sulfate52$2,692
SynthroidLevothyroxine Sodium30$2,151
Gabapentin42$894
Atorvastatin Calcium60$662
Rosuvastatin Calcium63$661
Venlafaxine Hcl ErVenlafaxine Hcl19$604
Amlodipine Besylate63$562
Montelukast Sodium35$544
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst31$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$274$67,67954 claims
GSKTrelegy Ellipta$237$37,83430 claims
Boehringer IngelheimJardiance$47$32,11131 claims
Novo NordiskOzempic$194$24,42926 claims
AbbVieLinzess, Synthroid$611$9,13941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Zachary

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →